Alnylam EVP Sells $1.13M in Stock via 10b5-1 Plan and Tax Withholding
ALNYLAM PHARMACEUTICALS, INC.
Subscribe to track ALNY
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Alnylam EVP Sells $1.13M in Stock via 10b5-1 Plan and Tax Withholding
Company: ALNYLAM PHARMACEUTICALS, INC. (ALNY) Form: 4 | Filed: 2026-03-04 Significance: Low
Insider: Garg Pushkal Title: EVP Chief R&D | Relationship: Officer
Transaction: • Type: Sale (Combined Tax & Plan) • Shares: 3,492 • Price: ~$323.60 (Weighted Avg) • Value: ~$1,130,000 • Owned After: 23,406
Key Insight: Routine transaction mix: ~50% of sales were mandatory "sell-to-cover" for tax withholding on RSU vesting, and ~50% were pursuant to a 10b5-1 plan adopted in Nov 2025.
Market Context: Transaction represents <0.01% of the company's $44.15B market cap.
Comprehensive Analysis
SEC Filing Analysis: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Routine RSU vesting with mandatory tax sales and a pre-planned 10b5-1 sale; immaterial relative to market cap.
- Market Impact: Neutral - transaction volume is negligible for a large-cap biotech.
Company Information
| Field | Value |
|---|---|
| Company | ALNYLAM PHARMACEUTICALS, INC. |
| Ticker Symbol | ALNY |
| CIK | 0001178670 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Garg Pushkal |
| CIK | 0001829252 |
| Title/Position | EVP Chief R&D |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2026-03-03 |
| Transaction Code | S (Sale) & A (Grant) |
| Security Type | Common Stock |
| Shares Sold | 3,492 (Total) |
| Avg Price Per Share | ~$323.60 |
| Total Value Sold | ~$1,130,000 |
| Shares Owned After | 23,406 (Direct) |
| Ownership Type | Direct & Indirect |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | ~$1.13 Million |
| % of Market Cap | ~0.0026% |
| Shares Transacted | 3,492 |
| % of Shares Outstanding | ~0.0026% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a market cap of $44.15 billion, a $1.13 million sale is statistically insignificant noise.
- Ownership Concentration: The insider retains 23,406 direct shares plus unvested options, maintaining alignment with shareholders.
- Transaction Context:
- Grants: Insider received 4,769 RSUs and 10,480 Stock Options (Strike $325.07).
- Sales: 1,717 shares were sold automatically to cover taxes (Code F equivalent). 1,775 shares were sold via a 10b5-1 plan.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The sales are largely administrative (tax withholding) or pre-planned (10b5-1). The volume is too low to impact price action.
Volume & Sentiment
- Expected Volume Impact: None.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- 10b5-1 Plan: The discretionary sales were executed under a plan adopted on November 20, 2025.
- Sell-to-Cover: Approximately half the volume sold was mandatory to satisfy statutory tax withholding requirements upon RSU vesting.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.